<DOC>
	<DOCNO>NCT03052569</DOCNO>
	<brief_summary>Expanded access RXDX-105 give patient cancer harbor RET alteration receive TKIs target RET alteration , qualify participation , otherwise unable access , ongoing clinical trial RXDX-105 .</brief_summary>
	<brief_title>Expanded Access RXDX-105 Cancers With RET Alterations</brief_title>
	<detailed_description />
	<criteria>Diagnosis advance cancer RET alteration Unable participate ongoing RXDX105 clinical trial Willing able provide write , sign informed consent Medically suitable treatment RXDX105 Prior treatment TKI activity RET alteration Currently enrol ongoing clinical study investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>